Die Inzidenz von SIBO bei Erwachsenen wird auf etwa 2,522% geschätzt. SIBO wird bei etwa 47,5% der Patienten mit Reizdarmsyndrom (IBS) beobachtet. Die Symptome betreffen hauptsächlich das Verdauungssystem und umfassen Blähungen, Gas, Durchfall und Verstopfung. Erkrankungen des Verdauungssystems können eng mit dem psychischen Zustand zusammenhängen, da der Darm manchmal als zweites Gehirn bezeichnet wird. Eine frühe Diagnose und die Einleitung geeigneter Maßnahmen sind daher von entscheidender Bedeutung, um das Gleichgewicht im Körper wiederherzustellen.
Small Intestinal Bacterial Overgrowth (SIBO): Pathophysiological Mechanisms, Diagnostic Considerations, and Clinical Manifestations
Small intestinal bacterial overgrowth (SIBO) represents a **disordered microbial ecology** within the small bowel, characterized by **excessive bacterial colonization**—both in terms of quantity and atypical species—within a segment where microbial presence is normally minimal. The gastrointestinal microbiota can be categorized into three primary groups: **commensal beneficial strains** (e.g., *Lactobacillus plantarum*, *Bifidobacterium breve*), **opportunistic pathogens with conditional virulence** (such as *Escherichia coli* or *Streptococcus salivarius*), and **frankly pathogenic microorganisms** (including *Clostridium botulinum*). This delicate balance is maintained through multiple physiological safeguards, including the **acidic gastric barrier** (pH range of 1.5–3.5), **digestive enzyme activity** (pepsin, pancreatic lipase), and the **bacteriostatic effects of bile acids**. Disruptions to these mechanisms—such as **hypochlorhydria**, **impaired intestinal motility**, or **ileocecal valve incompetence**—predispose the small intestine to colonization by colonic-type bacteria. The **core pathophysiological defect in SIBO** involves dysfunction of the **migrating motor complex (MMC)**, a **cyclical, interdigestive peristaltic activity** designed to **clear the small bowel of residual nutrients and bacteria** between meals. The **Phase III MMC**, lasting approximately 5–10 minutes every 90–120 minutes, generates powerful propagating contractions to expel luminal contents. Impairment of this process leads to **intestinal stasis** and subsequent bacterial proliferation. Clinically, SIBO presents with a **heterogeneous spectrum of symptoms**, predominantly **gastrointestinal in nature**, including bloating, diarrhea, constipation, abdominal pain, and food intolerances. Due to **significant overlap with irritable bowel syndrome (IBS)**, diagnostic clarification often requires **hydrogen-methane breath testing (lactulose/glucose challenge)** or **small bowel aspiration with quantitative culture** to confirm microbial overgrowth.
Sie haben begonnen, einen PRO-Artikel zu lesen
Sie können das erste Kapitel lesen. Um den gesamten Artikel zu lesen und alle Inhalte freizuschalten, wechseln Sie zum PRO-Konto.